Patient-to-Patient Transmission of Klebsiella pneumoniae Carbapenemase Variants with Reduced Ceftazidime-Avibactam Susceptibility. Antimicrob Agents Chemother 2019 Oct;63(10)
Date
07/25/2019Pubmed ID
31332070Pubmed Central ID
PMC6761506DOI
10.1128/AAC.00955-19Scopus ID
2-s2.0-85072570497 (requires institutional sign-in at Scopus site) 21 CitationsAbstract
We report patient-to-patient transmission of Enterobacter hormaechei isolates with reduced susceptibility to ceftazidime-avibactam due to production of KPC-40, a variant of KPC-3 with a two-amino-acid insertion in the Ω-loop region (L167_E168dup). The index patient had received a prolonged course of ceftazidime-avibactam therapy, whereas the second patient had not received the agent and still became colonized with the KPC-40-producing strain. The complex dynamics of KPC (Klebsiella pneumoniae carbapenemase) described here highlight several key diagnostic and therapeutic considerations.
Author List
Munoz-Price LS, Reeme AE, Buchan BW, Mettus RT, Mustapha MM, Van Tyne D, Shields RK, Doi YAuthors
Blake W. Buchan PhD Professor in the Pathology and Laboratory Medicine department at Medical College of WisconsinAllison Reeme in the CTSI department at Medical College of Wisconsin - CTSI
MESH terms used to index this publication - Major topics in bold
Anti-Bacterial AgentsAzabicyclo Compounds
Bacterial Proteins
Ceftazidime
Drug Combinations
Drug Resistance, Multiple, Bacterial
Klebsiella pneumoniae
Microbial Sensitivity Tests
beta-Lactamases
